Soros Capital Management’s Twist Bioscience TWST Stock Holding History

Soros Capital Management’s Portfolio TWST Stock Details TWST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-27,000	Closed	-$2.89M	–	57
2021 Q3	$2.89M	Hold	27,000	–	–	0.53%	25
2021 Q2	$3.6M	Buy	+27,000	New	+$3.14M	0.38%	41

Other funds holding TWST

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Soros Capital Management's TWST Position: Q4 2021 in Review

Soros Capital Management sold out of Twist Bioscience (TWST) in Q4 2021, closing a stake of 27,000 shares — an estimated $2.89M sold.

Soros Capital Management first reported a position in TWST in Q2 2021 and held it in 2 quarters. The position peaked at $3.6M in Q2 2021. 236 funds tracked by Wall St. Rank hold TWST as of Q4 2021.

Soros Capital Management reported no remaining Twist Bioscience position as of Q4 2021 after selling out during the quarter.
Soros Capital Management sold 27,000 Twist Bioscience shares in Q4 2021, an estimated $2.89M.
Soros Capital Management first reported a position in Twist Bioscience in Q2 2021 and held it in 2 quarters.
Soros Capital Management's Twist Bioscience position peaked at $3.6M in Q2 2021.
236 funds tracked by Wall St. Rank held Twist Bioscience as of Q4 2021.

Based on Soros Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.